News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Roche (RHHBY) Updates Late-Stage Pipeline; Highlights Drugs Outside Core Cancer Focus



10/1/2013 8:17:31 AM

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

Swiss drugmaker Roche will highlight its most promising treatments in oncology, immunology and ophthalmology at an investor event on Tuesday, as it seeks to show its potential in and beyond its core cancer expertise. The world's biggest maker of cancer medicines cited etrolizumab in inflammatory bowel disease and lampalizumab, a treatment for the dry form of age-related macular degeneration (AMD), as among its most promising therapies. The Basel-based firm is also developing so-called "follow on" drugs that it hopes will replace or breathe new life into old cancer products.

Help employers find you! Check out all the jobs and post your resume.

Read at Reuters


comments powered by Disqus
Reuters
Roche
 
 

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES